Development of a Gastric Cancer Screening Intervention for H. Pylori Carriers Based on the Health Belief Model (HBM-GCS)
Development of a Gastric Cancer Screening Intervention Program for Helicobacter Pylori Carriers Based on the Health Belief Model
Gastric cancer (GC) remains a major global public health challenge. It often causes no obvious symptoms in the early stage, so most patients are diagnosed at an advanced stage. This highlights the importance of gastric cancer screening among high-risk populations to achieve early detection and improve survival outcomes. People infected with Helicobacter pylori (Hp) are at high risk of gastric cancer. Hp is one of the most common bacterial infections worldwide. It initiates carcinogenesis by triggering chronic atrophic gastritis and intestinal metaplasia, known as the Correa cascade. However, the acceptance of gastric cancer screening among Hp-infected individuals is still unsatisfactory. To our knowledge, there are few theory-based interventions designed to help Hp-infected people make decisions about gastric cancer screening and increase screening uptake. Therefore, based on our previous systematic review, this study aims to develop a health promotion program to improve gastric cancer screening participation among Hp-infected individuals in mainland China. Participants in the intervention group will receive a comprehensive health promotion program, including a 30-minute health education session. They will receive a 15-minute telephone follow-up with gastric cancer screening information in week 2, and additional 10-minute telephone follow-ups at weeks 2, 4, and 6 to help participants identify and overcome barriers to gastric cancer screening. Participants in the control group will receive routine care. Data on gastric cancer screening participation will be collected at the end of the intervention. Findings from this study will be valuable for gastric cancer prevention among people with Hp infection.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Participants in the intervention group will receive the following multi-session health promotion intervention. The details are as follows.
Screening benefit construction (30 min). In the first week, education will be delivered through face-to-face for the following information:
(1) Hp infection and increased gastric cancer risk; (2) gastric cancer screening recommendations regarding eligibility, available screening tests, and recommended screening intervals; (3) pros/advantages of undergoing gastric cancer screening; (4) cons/disadvantages or uncertainties of undergoing gastric cancer screening; (5) implications of positive screening results; and (6) health costs and service information. The educational material will be presented in a self-made manual, which will be explained and distributed to each participant.
Screening barrier navigation (15 min). It will be conducted in the second week by telephone. The nurse counsellor will help participants resolve individual barriers related to gastric cancer screening. The tailored content includes:
(1) Q&A about gastroscopy screening; (2) gastroscopy appointment procedure; (3) hospital and transportation information; (4) medical insurance consultation; (5) precautions for the examination.
Screening self-efficacy reinforcement (10 min each). At the fourth and sixth weeks, the nurse counsellor will work with participants through a telephone-based way (with WeChat as an auxiliary tool) to strengthen confidence in completing gastric cancer screening, in which participants will: (1) track the progress of screening arrangements; (2) receive home health guidance while waiting for the screening examination.
Participants in the control group will receive routine health care for Hp infection without this theory-based gastric cancer screening promotion program.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Mengyao Gao, MN
- Telefonnummer: (86)15870682367
- E-Mail: 15870682367@163.com
Studieren Sie die Kontaktsicherung
- Name: Caixia Li, PhD
- Telefonnummer: (86) 19867712062
- E-Mail: licx23@mail.sysu.edu.cn
Studienorte
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518000
- The University of Hong Kong-Shenzhen Hospital
-
Kontakt:
- Mengyao Gao, MN
- Telefonnummer: (86)15870682367
- E-Mail: 15870682367@163.com
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Aged between 45 and 74 years.
- Diagnosed with *Helicobacter pylori* infection confirmed by urea breath test (UBT), serological antibody test, or stool antigen test.
- Have adequate communication, reading, and comprehension ability.
- Provide informed consent, voluntarily participate in the study, and cooperate with all study procedures.
Exclusion Criteria:
-
1. Previously diagnosed with gastric cancer or other advanced malignant tumors. 2. Cognitive impairment, severe hepatic or renal insufficiency, psychiatric disorders, or severe physical illness that prevents cooperation with the interview.
3. Pregnant or breastfeeding women.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Screening
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Experimental: Health Belief Model-based intervention group
Provide education, tailored information, barrier counseling, and decision support regarding gastric cancer screening for Helicobacter pylori-infected individuals. |
Provide health education, tailored information, barrier counseling and follow-up regarding gastric cancer screening for Helicobacter pylori-infected individuals. |
|
Sonstiges: Control group
Usual care provided by the hospital, including one-page written education material on gastroscopy. |
Usual care provided by the hospital, including one-page written education material on gastroscopy. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Gastric cancer screening intention
Zeitfenster: Immediately and 6 weeks after intervention
|
Participants' behavioral tendency and psychological readiness to actively seek and undergo gastroscopy within the next 5 years. |
Immediately and 6 weeks after intervention
|
|
Gastroscopy completion rate
Zeitfenster: 6 weeks after intervention
|
An objective outcome is defined as the number of participants who complete gastroscopy after intervention. The gastroscopy completion rates among Helicobacter pylori-infected participants in the two groups will be compared, serving as the key quantitative indicator to evaluate whether the intervention improves actual screening behavior. |
6 weeks after intervention
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Gastric cancer screening knowledge score
Zeitfenster: Immediately and 6 weeks after intervention
|
Assessed with knowledge items from Huang et al. (2022). The scale measures participants' knowledge of gastric cancer risk factors and warning symptoms, consisting of 24 items on risk factors and 14 items on warning symptoms. |
Immediately and 6 weeks after intervention
|
|
Total score of the Health Belief Model (HBM) questionnaire for gastric cancer screening
Zeitfenster: Immediately and 6 weeks after intervention
|
This subscale was developed based on the five-dimensional HBM framework proposed by Becker (1974), including perceived susceptibility to gastric cancer (3 items), perceived severity (3 items), perceived benefits of gastric cancer screening (2 items), perceived barriers to screening (5 items), and cues to action (3 items). The total score of the five dimensions is calculated. |
Immediately and 6 weeks after intervention
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Mengyao Gao, MN, Kiang Wu Nursing College of Macau(KWNC)
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- Gastric Cancer Screening
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .